Entries by Philip Rye

AlgiPharma is recruiting again!

R&D Project Manager at AlgiPharma Application Deadline:  28.01.2024 The candidate will proactively manage the day-to-day running of multiple R&D projects, coordinating with key internal and external stakeholders to advance our portfolio of alginate oligosaccharide technologies for drug delivery, drug conjugates and stand-alone API for cystic fibrosis, COPD and infectious diseases. In addition to the basic […]

AlgiPharma Presenting at the Lipid Nanoparticle Development Europe Summit

We are delighted to have been invited to speak at the 2nd Lipid Nanoparticle Development Europe Summit, taking place 17-19th October 2023, in Amsterdam. With lipid nanoparticles (LNPs) moving beyond mRNA vaccines, AlgiPharma is developing its technology to improve the delivery and efficacy of LNP therapeutics. Dr. Philip Rye, Chief Scientific Officer at AlgiPharma will […]

AlgiPharma announces the appointment of Dr. Preston W. Campbell MD to the Board

We are extremely pleased to announce the appointment of Preston W. Campbell to the AlgiPharma Board as a non-executive Board Member. His experience and wisdom will be invaluable in guiding the AlgiPharma team and their alginate technology closer to market.   Dr. Preston Campbell served at the Cystic Fibrosis Foundation for 25 years where he […]

AlgiPharma presented at Lipid Nanoparticle Summit in Boston

AlgiPharma attended the LNP Formulation & Process Development conference in Boston, MA (17-19th April). Chief Scientific Officer Dr. Philip Rye presented AlgiPharma’s novel alginate oligosaccharide technology for overcoming inhalation barriers for LNP delivered therapeutics. His presentation highlighted the benefits and challenges associated with the inhalation delivery route, and how AlgiPharma’s technology can mediate the effective […]

AlgiPharma announces the appointment of Dr. Charles A Johnson and Mr. Mike Walters to the Board

We are extremely pleased to announce the appointment of two experienced and high-calibre pharmaceutical experts to the AlgiPharma Board as non-executive Board Members. Their combined expertise will be invaluable in bringing AlgiPharma’s alginate technology closer to market. Dr Charles Johnson is an independent consultant with over 30 years’ experience in the biotechnology industry. He gained […]

AlgiPharma Welcomes a New Member to the Team

AlgiPharma welcomes Mr Ole Tobias Fevang to the AlgiPharma team as accounting manager in support of the Norwegian operations. He has a master’s degree in finance from BI Norwegian Business School. He has previously worked at Norwegian banks (DNB Bank AS and Sparebanken Øst), and more recently four years as an accountant at the international […]

AlgiPharma Attends the LNP Summit Congress in London

AlgiPharma attends and presents data on its alginate oligosaccharide technology platform at the Lipid Nanoparticles Development Summit 18th-20th October in London.   About AlgiPharma AS: AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the […]

AlgiPharma Adds to its Intellectual Property Portfolio

AlgiPharma was recently granted patent protection for its United States Patent No. 11413306 (15/766272) National Phase of PCT Application PCT/EP2016/073931 for “Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract”. This adds to AlgiPharma’s growing patent portfolio.   About AlgiPharma AS: AlgiPharma AS is a clinical stage pharmaceutical company, founded […]

AlgiPharma Attends Annual European Cystic Fibrosis Congress in Rotterdam

AlgiPharma attends the annual ECFS congress in Rotterdam, continuing to support and learn about new developments for the treatment of people with Cystic Fibrosis.   About AlgiPharma AS: AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of […]

AlgiPharma Adds to its Intellectual Property Portfolio

AlgiPharma was recently granted patent protection in its ongoing National Phase of PCT Application PCT/EP2017/076926 for “Bacitracin-alginate oligomer conjugates”. This adds to AlgiPharma’s growing patent portfolio.   About AlgiPharma AS: AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the […]